The burgeoning popularity of tirzepatide , initially for diabetes , is creating significant interest within the UK , prompting a notable shift in peptide trends. Obtaining these medications remains a complex situation , with National Health Service provision currently limited and private clinics offering therapy at a substantial price. Worries are